PharmaBlock Sciences Nanjing saw no growth in patent filings and highest growth of 0.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of PharmaBlock Sciences Nanjing’s patent filings and grants. Buy the databook here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
PharmaBlock Sciences Nanjing has been focused on protecting inventions in Canada(CA) with one publication in Q2 2024
The Canada(CA) Patent Office dominates the patent grants with nearly 50% of grants. The Canada(CA), China(CN), and European Patent Office(EPO) patent Office are among the top ten patent offices where PharmaBlock Sciences Nanjing is filings its patents. Among the top granted patent authorities, PharmaBlock Sciences Nanjing has 50% of its grants in Canada(CA) and 50% in China(CN).
Roche could be the strongest competitor for PharmaBlock Sciences Nanjing
Patents related to climate change lead PharmaBlock Sciences Nanjing's portfolio
PharmaBlock Sciences Nanjing has the highest number of patents in climate change.in Q2 2024.
For comprehensive analysis of PharmaBlock Sciences Nanjing's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

